First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions

Papers of special note have been highlighted as: • of interest

References

• 1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 553(7689), 446–454 (2018).
  Medline CASGoogle Scholar
• 2. Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review. JAMA 322(8), 764–774 (2019).
  Medline CASGoogle Scholar
• 3. Reck M, Rodríguez-Abreu D, Robinson AG et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37(7), 537–546 (2019).
  Medline CASGoogle Scholar
• 4. Herbst RS, Giaccone G, de Marinis F et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N. Engl. J. Med. 383(14), 1328–1339 (2020).
  Medline CASGoogle Scholar
• 5. Holmes M, Mahar A, Lum T, Kao S, Cooper WA. Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status. J. Clin. Pathol. 74(2), 123–128 (2021).
  Medline CASGoogle Scholar
• 6. Borghaei H, Langer CJ, Gadgeel S et al. 24-Month overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 14(1), 124–129 (2019).
  Medline CASGoogle Scholar
• 7. Gadgeel S, Rodríguez-Abreu D, Speranza G et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 38(14), 1505–1517 (2020). • This was the study that led to the approval of first-line (1L) pembrolizumab plus chemotherapy for patients with metastatic non-squamous non-small-cell lung cancer regardless of PD-L1 expression.The present study found that pembrolizumab plus chemotherapy yielded better efficacy than other immune checkpoint inhibitors plus chemotherapy and chemotherapy plus bevacizumab.
  Medline CASGoogle Scholar
• 8. West H, McCleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20(7), 924–937 (2019). • This study led to the approval of 1L atezolizumab plus chemotherapy for patients with advanced non-small-cell lung cancer.
  Medline CASGoogle Scholar
• 9. Paz-Ares L, Ciuleanu TE, Cobo M et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 22(2), 198–211 (2021).
  Medline CASGoogle Scholar
• 10. Huang LT, Cao R, Wang YR et al. Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomized control trials. BMC Cancer 21(1), 426 (2021).
  Medline CASGoogle Scholar
• 11. Liu Y, Li HM, Wang R. Effectiveness and safety of adding bevacizumab to platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer: a meta-analysis. Front. Med. (Lausanne) 8, 616380 (2021).
  MedlineGoogle Scholar
• 12. Reck M, Wehler T, Orlandi F et al. Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab versus bevacizumab plus chemotherapy in non-small-cell lung cancer. J. Clin. Oncol. 38(22), 2530–2542 (2020).
  MedlineGoogle Scholar
• 13. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann. Intern. Med. 162(11), 777–784 (2015).
  MedlineGoogle Scholar
• 14. Higgins JP, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).
  MedlineGoogle Scholar
• 15. Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P. A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 12(1), 1–17 (2014).
  Google Scholar
• 16. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 8(10), e76654 (2013).
  Medline CASGoogle Scholar
• 17. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 26(9), 753–767 (2008).
  MedlineGoogle Scholar
• 18. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64(2), 163–171 (2011).
  MedlineGoogle Scholar
• 19. Spiegelhalter DJ, Best NG, Carlin BR et al. Bayesian measures of model complexity and fit. J. R. Stat. Soc. B. 64, 583–616 (2002).
  Google Scholar
• 20. Schünemann HJ, Oxman AD, Vist GE et al. Confidence intervals. In: Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0). Higgins JGreen S (Eds). The Cochrane Collaboration, London, UK (2011). https://handbook-5-1.cochrane.org/
  Google Scholar
• 21. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat. Med. 29(7-8), 932–944 (2010).
  Medline CASGoogle Scholar
• 22. Paz-Ares L, Ciuleanu TE, Yu X et al. Nivolumab (NIVO) 1 platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 – part 2 final analysis. Ann. Oncol. 30(Suppl. 11), xi67–xi68 (2019).
  Google Scholar
• 23. Zhou C, Chen G, Huang Y et al. OA04.03 A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced/metastatic non-squamous non-small cell lung cancer. J. Thorac. Oncol. 14(10), S215–S216 (2019).
  Google Scholar
• 24. Papadimitrakopoulou V, Cobo M, Bordoni R et al. IMpower132: PFS and safety results with 1L atezolizumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. J. Thorac. Oncol. 13(10), S332–S333 (2018).
  Google Scholar
• 25. Reck M, von Pawel J, Zatloukal P et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann. Oncol. 21(9), 1804–1809 (2010).
  Medline CASGoogle Scholar
• 26. Galetta D, Cinieri S, Pisconti S et al. Cisplatin/pemetrexed followed by maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italia Meridionale) ERACLE phase III randomized trial. Clin. Lung Cancer 16(4), 262–273 (2015).
  Medline CASGoogle Scholar
• 27. Zhou C, Wu YL, Chen G et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 33(19), 2197–2204 (2015). • In this study, overall survival was significantly prolonged with carboplatin/paclitaxel plus bevacizumab (median 24.3 months), which is comparable with the results in KEYNOTE-189.
  Medline CASGoogle Scholar
• 28. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542–2550 (2006).
  Medline CASGoogle Scholar
• 29. Niho S, Kunitoh H, Nokihara H et al. Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76(3), 362–367 (2012).
  MedlineGoogle Scholar
• 30. Koyama R, Udagawa H, Sugiyama E et al. 1436P randomized phase II study comparing cisplatin + pemetrexed + bevacizumab with carboplatin + paclitaxel + bevacizumab in treatment-naive advanced non-squamous non-small-cell lung cancer (CLEAR study). Ann. Oncol. 29(Suppl. 8), viii493–viii547 (2018).
  Google Scholar
• 31. Patel JD, Socinski MA, Garon EB et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 31(34), 4349–4357 (2013).
  Medline CASGoogle Scholar
• 32. Zinner RG, Obasaju CK, Spigel DR et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. J. Thorac. Oncol. 10(1), 134–142 (2015).
  Medline CASGoogle Scholar
• 33. Liu T, Ding S, Dang J, Wang H, Chen J, Li G. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis. J. Thorac. Dis. 11(7), 2899–2912 (2019).
  MedlineGoogle Scholar
• 34. Peng TR, Lin HH, Tsai FP, Wu TW. Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: a systematic review and network meta-analysis. Thorac. Cancer 12(21), 2873–2885 (2021).
  MedlineGoogle Scholar
• 35. Garcia J, Hurwitz HI, Sandler AB et al. Bevacizumab (Avastin^®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017 (2020).
  Medline CASGoogle Scholar
• 36. Frentzas S, Simoneau E, Bridgeman VL et al. Vessel co-option mediates resistance to antiangiogenic therapy in liver metastases. Nat. Med. 22(11), 1294–1302 (2016).
  Medline CASGoogle Scholar
• 37. Coelho AL, Gomes MP, Catarino RJ et al. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches? Oncotarget 8(24), 39795–398042 (2017).
  MedlineGoogle Scholar
• 38. Cantelmo AR, Dejos C, Kocher F et al. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019. Curr. Opin. Oncol. 32(1), 44–53 (2020).
  MedlineGoogle Scholar
• 39. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint inhibitors therapy. Cancer Discov. 8(9), 1069–1086 (2018).
  MedlineGoogle Scholar
• 40. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39(1), 1–10 (2013).
  MedlineGoogle Scholar
• 41. Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann. Oncol. 27(8), 1492–1504 (2016).
  Medline CASGoogle Scholar
• 42. Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125(9), 3384–3391 (2015).
  MedlineGoogle Scholar
• 43. Lickliter JD, Gan HK, Voskoboynik M et al. A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia. Drug Des. Devel. Ther. 14, 1177–1189 (2020).
  Medline CASGoogle Scholar
• 44. Shimizu T, Seto T, Hirai F et al. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Invest. New Drugs 34(3), 347–354 (2016).
  Medline CASGoogle Scholar
• 45. Wang C, Thudium KB, Han M et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2(9), 846–856 (2014).
  Medline CASGoogle Scholar
• 46. Fu J, Wang F, Dong L-H et al. Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol. Sin. 38(5), 710–718 (2017).
  Medline CASGoogle Scholar
• 47. Scagliotti G, Brodowicz T, Shepherd FA et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J. Thorac. Oncol. 6(1), 64–70 (2011).
  MedlineGoogle Scholar
• 48. Cavazzoni A, Digiacomo G, Alfieri R et al. Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer. Cancers (Basel) 12(3), 666 (2020).
  CASGoogle Scholar
• 49. Schmid S, Diem S, Li Q et al. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol. Immunother. 67(12), 1825–1832 (2018).
  Medline CASGoogle Scholar
• 50. Tumeh PC, Hellmann MD, Hamid O et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol. Res. 5(5), 417–424 (2017).
  Medline CASGoogle Scholar
• 51. Voron T, Marcheteau E, Pernot S et al. Control of the immune response by pro-angiogenic factors. Front. Oncol. 4, 70 (2014).
  MedlineGoogle Scholar
• 52. Fukumura D, Kloepper J, Amoozgar Z et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15(5), 325–340 (2018).
  Medline CASGoogle Scholar
• 53. Reinmuth N, Jauch A, Xu EC et al. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer 62(2), 193–201 (2008).
  MedlineGoogle Scholar
• 54. Tanaka I, Morise M, Miyazawa A et al. Potential benefits of bevacizumab combined with platinum-based chemotherapy in advanced non-small-cell lung cancer patients with EGFR mutation. Clin. Lung Cancer 21(3), 273–280.e4 (2020).
  Medline CASGoogle Scholar